Pharmacoeconomics - Open

OCT 2, 2026 · JOURNAL ARTICLE

Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients

Pharmacoeconomics - Open

Hepatocellular carcinoma (HCC) is a cancer with rising incidence and economic burden. However, evidence on healthcare resource utilization (HCRU) and associated costs is scarce in

OCT 2, 2026 · JOURNAL ARTICLE

Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective

Pharmacoeconomics - Open

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have transformed the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) brea